Lionco Pharmaceutical Group (603669) Fundamentals 2026 — Revenue Analysis | SniperIQ
Lionco Pharmaceutical Group (603669) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥3.9B, trading at ¥5.45 on the SHH. This SniperIQ fundamentals page covers Lionco Pharmaceutical Group's valuation, profitability (net margin -47.8%), revenue (¥322M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lionco Pharmaceutical Group's market cap?
Lionco Pharmaceutical Group (603669) has a market capitalization of approximately ¥3.9B, trading at ¥5.45 on the SHH. Market cap moves with the live share price.
What is Lionco Pharmaceutical Group's P/E ratio?
Lionco Pharmaceutical Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lionco Pharmaceutical Group?
Lionco Pharmaceutical Group runs a net profit margin of -47.8%, a gross margin of 40.1%, and an operating margin of -33.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lionco Pharmaceutical Group generate?
Lionco Pharmaceutical Group reported revenue of ¥322M for fiscal year 2025, with net income of -¥193M and earnings per share (EPS) of -0.27. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lionco Pharmaceutical Group pay a dividend?
Lionco Pharmaceutical Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Lionco Pharmaceutical Group financially healthy?
Lionco Pharmaceutical Group carries a debt-to-equity ratio of 0.56x and a current ratio of 1.15x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lionco Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lionco Pharmaceutical Group (603669) the key facts are: market cap ¥3.9B, revenue ¥322M, 52-week range 4.01-8.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lionco Pharmaceutical Group's full fundamentals live
Get Lionco Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.